In this episode, we’re joined by Dr. Marc Hoffmann from The University of Kansas Cancer Center, to explore chronic lymphocytic leukemia (CLL)—what it is, how it’s treated today, and where research is headed. Dr. Hoffmann shares insights on treatment goals, side effect management, and the importance of shared decision making. We also touch on emerging therapies—including CAR T-cell therapy and bispecifics—and end with a message of hope for those navigating life after a CLL diagnosis.

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by AbbVie Inc., BeOne Medicines and Genentech, A Member of the Roche Group.

The post Partnering in Care: Chronic Lymphocytic Leukemia (CLL) first appeared on The Bloodline with Blood Cancer United Podcast.

Primary Central Nervous System Lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma that affects the brain, spinal cord, or eyes. In this episode, Dr. Lakshmi Nayak of Dana-Farber Cancer Institute, helps us better understand this uncommon type of lymphoma.  From early signs and symptoms to diagnosis, treatment options, and the latest clinical trials, Dr. Nayak breaks it all down in a clear and compassionate way.

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by Ono Pharma USA, Inc.

The post Breaking Down Primary CNS Lymphoma: From Rare Diagnosis to Growing Progress first appeared on The Bloodline with Blood Cancer United Podcast.

“If you have a rare disease, it’s not rare to you.”

In this episode, Dr. Naveen Pemmaraju of MD Anderson Cancer Center in Houston, TX, sheds light on the latest treatment advancements for myelofibrosis. The pace of scientific discovery for rare diseases is moving at a fast rate, resulting in better outcomes for myelofibrosis patients.

*This episode was recorded on Rare Disease Day, February 29, 2024

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by: GSK plc.

The post Hope for a Rare Disease: Myelofibrosis first appeared on The Bloodline with Blood Cancer United Podcast.

Remarkable progress has been made in the treatment of myeloma over the past decade, giving patients and families much hope for the future. In this episode, we speak to Dr. Nishi Shah of Montefiore Einstein Comprehensive Cancer Center in New York City. While the wide variety of therapies available to patients are discussed, this episode also focuses on the newest, cutting-edge therapies for myeloma, such as CAR T-cell therapy and bispecific antibodies.  

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by: AbbVie Inc.; Genentech, Inc. & Biogen; and Johnson & Johnson.

The post How New Therapies Are Changing The Future of Myeloma first appeared on The Bloodline with Blood Cancer United Podcast.